GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

Lenvatinib plus pembrolizumab did not improve PFS or OS over chemotherapy in patients with advanced or recurrent endometrial ...

FYB-206 is under development for the treatment of malignant melanoma (black skin cancer) and non-small cell lung cancer. The drug candidate is a pembrolizumab biosimilar. It acts by targeting ...

Unlike existing and first-generation immunotherapies that exclusively target immune T cells, these monoclonal antibodies are engineered to precise ...

The following is a summary of “Neoadjuvant Pembrolizumab in Stage I-III Deficient Mismatch Repair Colon Cancer: A Clinical ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...

James “Jimmy” Carter, the 39th President of the United States, passed away last week on December 29, after 22 months in Hospice care.  At | Cancer ...

The following is a summary of “A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib ...

Viracta Therapeutics announced the closure of a phase II trial of its combination therapy of the histone deacetylase ...

Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (Keytruda) in the KeyVibe programme. Favezelimab is being evaluated as an investigational fixed-dose ...